Signe Carlson1, Deri Helterline1, Laura Asbe1, Sarah Dupras2, Elina Minami1, Stephen Farris1, April Stempien-Otero3. 1. Departments of Medicine, University of Washington School of Medicine, United States. 2. Departments of Pathology, University of Washington School of Medicine, United States. 3. Departments of Medicine, University of Washington School of Medicine, United States; Departments of Pathology, University of Washington School of Medicine, United States.
Abstract
BACKGROUND: Macrophages (mac) that over-express urokinase plasminogen activator (uPA) adopt a profibrotic M2 phenotype in the heart in association with cardiac fibrosis. We tested the hypothesis that cardiac macs are M2 polarized in infarcted mouse and human hearts and that polarization is dependent on mac-derived uPA. METHODS: Studies were performed using uninjured (UI) or infarcted (MI) hearts of uPA overexpressing (SR-uPA), uPA null, or nontransgenic littermate (Ntg) mice. At 7days post-infarction, cardiac mac were isolated, RNA extracted and M2 markers Arg1, YM1, and Fizz1 measured with qrtPCR. Histologic analysis for cardiac fibrosis, mac and myofibroblasts was performed at the same time-point. Cardiac macs were also isolated from Ntg hearts and RNA collected after primary isolation or culture with vehicle, IL-4 or plasmin and M2 marker expression measured. Cardiac tissue and blood was collected from humans with ischemic heart disease. Expression of M2 marker CD206 and M1 marker TNFalpha was measured. RESULTS: Macs from WT mice had increased expression of Arg1 and Ym1 following MI (41.3±6.5 and 70.3±36, fold change vs UI, n=8, P<0.007). There was significant up-regulation of cardiac mac Arg1 and YM1 with MI in both WT and uPA null mice (n=4-9 per genotype and condition). Treatment with plasmin increased expression of Arg1 and YM1 in cultured cardiac macs. Histologic analysis revealed increased density of activated fibroblasts and M2 macs in SR-uPA hearts post-infarction with associated increases in fibrosis. Cardiac macs isolated from human hearts with ischemic heart disease expressed increased levels of the M2 marker CD206 in comparison to blood-derived macs (4.9±1.3). CONCLUSIONS: Cardiac macs in mouse and human hearts adopt a M2 phenotype in association with fibrosis. Plasmin can induce an M2 phenotype in cardiac macs. However, M2 activation can occur in the heart in vivo in the absence of uPA indicating that alternative pathways to activate plasmin are present in the heart. Excess uPA promotes increased fibroblast density potentially via potentiating fibroblast migration or proliferation. Altering macrophage phenotype in the heart is a potential target to modify cardiac fibrosis.
BACKGROUND: Macrophages (mac) that over-express urokinase plasminogen activator (uPA) adopt a profibrotic M2 phenotype in the heart in association with cardiac fibrosis. We tested the hypothesis that cardiac macs are M2 polarized in infarctedmouse and human hearts and that polarization is dependent on mac-derived uPA. METHODS: Studies were performed using uninjured (UI) or infarcted (MI) hearts of uPA overexpressing (SR-uPA), uPA null, or nontransgenic littermate (Ntg) mice. At 7days post-infarction, cardiac mac were isolated, RNA extracted and M2 markers Arg1, YM1, and Fizz1 measured with qrtPCR. Histologic analysis for cardiac fibrosis, mac and myofibroblasts was performed at the same time-point. Cardiac macs were also isolated from Ntg hearts and RNA collected after primary isolation or culture with vehicle, IL-4 or plasmin and M2 marker expression measured. Cardiac tissue and blood was collected from humans with ischemic heart disease. Expression of M2 marker CD206 and M1 marker TNFalpha was measured. RESULTS: Macs from WT mice had increased expression of Arg1 and Ym1 following MI (41.3±6.5 and 70.3±36, fold change vs UI, n=8, P<0.007). There was significant up-regulation of cardiac mac Arg1 and YM1 with MI in both WT and uPA null mice (n=4-9 per genotype and condition). Treatment with plasmin increased expression of Arg1 and YM1 in cultured cardiac macs. Histologic analysis revealed increased density of activated fibroblasts and M2 macs in SR-uPA hearts post-infarction with associated increases in fibrosis. Cardiac macs isolated from human hearts with ischemic heart disease expressed increased levels of the M2 marker CD206 in comparison to blood-derived macs (4.9±1.3). CONCLUSIONS: Cardiac macs in mouse and human hearts adopt a M2 phenotype in association with fibrosis. Plasmin can induce an M2 phenotype in cardiac macs. However, M2 activation can occur in the heart in vivo in the absence of uPA indicating that alternative pathways to activate plasmin are present in the heart. Excess uPA promotes increased fibroblast density potentially via potentiating fibroblast migration or proliferation. Altering macrophage phenotype in the heart is a potential target to modify cardiac fibrosis.
Authors: Mingjie Yang; Lei Song; Lai Wang; Ada Yukht; Haley Ruther; Fuqiang Li; Minghui Qin; Homayon Ghiasi; Behrooz G Sharifi; Prediman K Shah Journal: J Am Coll Cardiol Date: 2018-08-21 Impact factor: 24.094
Authors: Neekun Sharma; Rishabh Dev; Anthony M Belenchia; Annayya R Aroor; Adam Whaley-Connell; Lakshmi Pulakat; Chetan P Hans Journal: Arterioscler Thromb Vasc Biol Date: 2019-02 Impact factor: 8.311
Authors: Michelle A Sugimoto; Ana Luíza C Ribeiro; Bruno R C Costa; Juliana P Vago; Kátia M Lima; Fernanda S Carneiro; Mylena Maira O Ortiz; Graziele Letícia N Lima; Aline A F Carmo; Renata M Rocha; Denise A Perez; Alessandra C Reis; Vanessa Pinho; Lindsey A Miles; Cristiana C Garcia; Mauro M Teixeira; Lirlândia P Sousa Journal: Blood Date: 2017-03-20 Impact factor: 22.113
Authors: Darrian Bugg; Logan R J Bailey; Ross C Bretherton; Kylie E Beach; Isabella M Reichardt; Kalen Z Robeson; Anna C Reese; Jagadambika Gunaje; Galina Flint; Cole A DeForest; April Stempien-Otero; Jennifer Davis Journal: Cell Stem Cell Date: 2022-02-16 Impact factor: 25.269
Authors: Aleksandra Gombozhapova; Yuliya Rogovskaya; Vladimir Shurupov; Mariya Rebenkova; Julia Kzhyshkowska; Sergey V Popov; Rostislav S Karpov; Vyacheslav Ryabov Journal: J Biomed Sci Date: 2017-02-07 Impact factor: 8.410